19790-96-6

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
5-Amino-3-(4-pyridyl)-isoxazole serves as a key intermediate in the synthesis of pyridinyl isoxazoles, which have demonstrated promising insecticidal and fungicidal activities. Its incorporation into these compounds enhances their bioactivity, making it a valuable component in the development of effective pesticides and other agrochemicals.
Used in Medicinal Chemistry and Drug Development:
Due to its structural attributes, 5-Amino-3-(4-pyridyl)-isoxazole is utilized in medicinal chemistry for the design and synthesis of novel therapeutic agents. Its presence in drug molecules can potentially influence pharmacokinetic and pharmacodynamic properties, contributing to the discovery of new drugs with improved efficacy and safety profiles.
Used in Coordination Chemistry as a Ligand:
5-Amino-3-(4-pyridyl)-isoxazole has been studied for its potential as a ligand in coordination chemistry. Its ability to form stable complexes with various metal ions is of interest for applications in catalysis, materials science, and the development of metal-based pharmaceuticals. 5-AMINO-3-(4-PYRIDYL)-ISOXAZOLE's coordination properties allow for the fine-tuning of metal ion reactivity and selectivity in these applications.

Upstream product

• 23821-37-6 3-oxo-3-(pyridin-4-yl)propanenitrile 
• 1570-45-2 isonicotinic acid ethylester 

Downstream Products

• 78831-29-5 3-(4-pyridyl)-5-(2-hydroxybenzoyl)isoxazolo<5,4-b>pyridine 
• 78831-11-5 6-(2-hydroxyphenyl)-5-nitro-3-(4-pyridyl)-isoxazolo<5,4-b>pyridine 
• 1105634-25-0 C₂HF₃O₂*C₁₆H₁₀F₃N₃O₃ 
• 1309580-83-3 C₂₂H₂₃FN₄O₄ 
• 1240521-25-8 (S)-tert-butyl 3-(4-chlorophenyl)-1-oxo-1-(3-(pyridin-4-yl)isoxazol-5-ylamino)propan-2-ylcarbamate 
• 1240521-36-1 tert-butyl (S)-(1-oxo-3-phenyl-1-((3-(pyridin-4-yl)isoxazol-5-yl)amino)propan-2-yl)carbamate trifluoroacetate 

Relevant academic research and scientific papers

Identification of diphenylalkylisoxazol-5-amine scaffold as novel activator of cardiac myosin

To identify novel potent cardiac myosin activator, a series of diphenylalkylisoxazol-5-amine compounds 4–7 have been synthesized and evaluated for cardiac myosin ATPase activation. Among the 37 compounds, 4a (CMA at 10 μM = 81.6%), 4w (CMA at 10 μM = 71.2%) and 6b (CMA at 10 μM = 67.4%) showed potent cardiac myosin activation at a single concentration of 10 μM. These results suggested that the introduction of the amino-isoxazole ring as a bioisostere for urea group is acceptable for the cardiac myosin activation. Additional structure–activity relationship (SAR) studies were conducted. Para substitution (-Cl, –OCH3, -SO2N(CH3)2) to the phenyl rings or replacement of a phenyl ring with a heterocycle (pyridine, piperidine and tetrahydropyran) appeared to attenuate cardiac myosin activation at 10 μM. Additional hydrogen bonding acceptor next to the amino group of the isoxazoles did not enhance the activity. The potent isoxazole compounds showed selectivity for cardiac myosin activation over skeletal and smooth muscle myosin, and therefore these potent and selective isoxazole compounds could be considered as a new series of cardiac myosin ATPase activators for the treatment of systolic heart failure.

SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS

Provided are picolinamide compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES

The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.